Atara Biotherapeutics (ATRA) Now Covered by Stifel Nicolaus

Share on StockTwits

Equities research analysts at Stifel Nicolaus assumed coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a report released on Wednesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $41.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 74.54% from the company’s current price.

A number of other research analysts have also commented on ATRA. BidaskClub upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 7th. Mizuho reiterated a “buy” rating and set a $62.00 price objective on shares of Atara Biotherapeutics in a research note on Thursday, May 9th. William Blair reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Thursday, May 16th. ValuEngine lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 17th. Finally, Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, April 30th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $42.75.

NASDAQ ATRA opened at $23.49 on Wednesday. Atara Biotherapeutics has a 12 month low of $22.05 and a 12 month high of $52.74. The company has a current ratio of 9.96, a quick ratio of 9.96 and a debt-to-equity ratio of 0.05. The company has a market cap of $1.13 billion, a P/E ratio of -4.46 and a beta of 2.11.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.48) by $0.04. Sell-side analysts predict that Atara Biotherapeutics will post -5.69 EPS for the current fiscal year.

In other Atara Biotherapeutics news, Director Joel S. Marcus sold 62,590 shares of Atara Biotherapeutics stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $36.07, for a total value of $2,257,621.30. Following the transaction, the director now owns 32,590 shares in the company, valued at $1,175,521.30. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Isaac E. Ciechanover sold 7,800 shares of Atara Biotherapeutics stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $24.61, for a total transaction of $191,958.00. Following the completion of the transaction, the chief executive officer now owns 332,243 shares in the company, valued at approximately $8,176,500.23. The disclosure for this sale can be found here. In the last 90 days, insiders sold 129,990 shares of company stock worth $4,678,666. 10.60% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of ATRA. JPMorgan Chase & Co. lifted its stake in shares of Atara Biotherapeutics by 35.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,202,912 shares of the biotechnology company’s stock worth $49,741,000 after purchasing an additional 315,921 shares during the last quarter. Man Group plc purchased a new stake in shares of Atara Biotherapeutics during the 3rd quarter worth $277,000. AQR Capital Management LLC increased its position in Atara Biotherapeutics by 12.7% during the 3rd quarter. AQR Capital Management LLC now owns 21,609 shares of the biotechnology company’s stock valued at $894,000 after buying an additional 2,439 shares in the last quarter. Teachers Advisors LLC increased its position in Atara Biotherapeutics by 1.8% during the 3rd quarter. Teachers Advisors LLC now owns 85,416 shares of the biotechnology company’s stock valued at $3,532,000 after buying an additional 1,525 shares in the last quarter. Finally, Legal & General Group Plc increased its position in Atara Biotherapeutics by 145.9% during the 3rd quarter. Legal & General Group Plc now owns 15,826 shares of the biotechnology company’s stock valued at $655,000 after buying an additional 9,391 shares in the last quarter.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Read More: Put Option Volume

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokerages Set FedEx Co.  Price Target at $200.77
Brokerages Set FedEx Co. Price Target at $200.77
SYNNEX  Issues Q3 Earnings Guidance
SYNNEX Issues Q3 Earnings Guidance
Paychex  Updates FY 2020 Earnings Guidance
Paychex Updates FY 2020 Earnings Guidance
IHS Markit  Updates FY19 Earnings Guidance
IHS Markit Updates FY19 Earnings Guidance
LyondellBasell Industries  Updates Q2 Earnings Guidance
LyondellBasell Industries Updates Q2 Earnings Guidance
Starbucks  Coverage Initiated by Analysts at Citigroup
Starbucks Coverage Initiated by Analysts at Citigroup


© 2006-2019 Ticker Report